MX2018015363A - Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease. - Google Patents

Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.

Info

Publication number
MX2018015363A
MX2018015363A MX2018015363A MX2018015363A MX2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A
Authority
MX
Mexico
Prior art keywords
celiac
celiac disease
treatment
methods
refractory
Prior art date
Application number
MX2018015363A
Other languages
Spanish (es)
Inventor
Leon Francisco
H Tsuji Wayne
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2018015363A publication Critical patent/MX2018015363A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
MX2018015363A 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease. MX2018015363A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
MX2018015363A true MX2018015363A (en) 2019-04-15

Family

ID=56292925

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015363A MX2018015363A (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.
MX2024001374A MX2024001374A (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024001374A MX2024001374A (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.

Country Status (11)

Country Link
EP (1) EP3472202A1 (en)
JP (2) JP2019521981A (en)
CN (1) CN109311972A (en)
AR (1) AR108790A1 (en)
AU (2) AU2016411388A1 (en)
BR (1) BR112018076287A2 (en)
CA (1) CA3020894A1 (en)
EA (1) EA201892707A1 (en)
MX (2) MX2018015363A (en)
TW (2) TW202327653A (en)
WO (1) WO2017217985A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991514A1 (en) 2016-12-21 2019-12-30 Сефалон, Инк. ANTIBODIES THAT SPECIALLY CONTACT THE IL-15 AND THEIR APPLICATION
EP3873521A2 (en) * 2018-10-31 2021-09-08 Tiziana Life Sciences PLC Composition and methods of treating inflammatory and autoimmune diseases
MX2024001934A (en) 2021-08-12 2024-03-04 Amgen Inc Antibody formulations.
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EA015897B1 (en) * 2003-02-26 2011-12-30 Генмаб А/С Use of human monoclonal antibody to il-15 comprising a composition and medical preparation (variants), composition and medical preparation containing them
JP2012516153A (en) * 2009-01-29 2012-07-19 アボット・ラボラトリーズ IL-1 binding protein
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Also Published As

Publication number Publication date
CN109311972A (en) 2019-02-05
EP3472202A1 (en) 2019-04-24
AU2016411388A1 (en) 2018-11-08
BR112018076287A2 (en) 2019-03-26
TW202327653A (en) 2023-07-16
JP2022001577A (en) 2022-01-06
MX2024001374A (en) 2024-02-27
WO2017217985A1 (en) 2017-12-21
AU2024205264A1 (en) 2024-08-22
EA201892707A1 (en) 2019-05-31
CA3020894A1 (en) 2017-12-21
JP2019521981A (en) 2019-08-08
TW201803591A (en) 2018-02-01
AR108790A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2018006578A (en) Topical pharmaceutical formulations for treating inflammatory-related conditions.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017015574A (en) Inhibitors of bruton's tyrosine kinase.
MD20170032A2 (en) Anti-TIGIT antibodies
MY192927A (en) Fused bicyclic compounds for the treatment of disease
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
NZ737399A (en) Ccr2 modulators
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2019015311A (en) Cannabidiolic acid esters compositions and uses thereof.
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
MX369623B (en) Fused bicyclic compounds for the treatment of disease.
MX2017002489A (en) Human therapeutic agents.
ZA201807438B (en) Methods of treating ocular conditions
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
PH12017500602A1 (en) Methods for treating ocular conditions
MX2024001374A (en) Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease.
EA201791937A1 (en) ANTI-INFLAMMATORY POLYPEPTIDES
MX370897B (en) Fused bicyclic compounds for the treatment of disease.
WO2018211324A8 (en) Prodrugs for the treatment of disease
JOP20190164B1 (en) Compositions and methods for treating farber disease
MX2018014034A (en) Fused bicyclic compounds for the treatment of disease.
PH12017501979A1 (en) Pharmaceutical compound